Member Info for Timber1234

A lot of nervous and impatient folk jumping ship now it’s back in the twenties. They’ll be kicking themselves in the not too distant future.

Very positive that people are buying into the dip. Sentiment is a very fickle thing!

Thanks ST. Great research. I agree - these are positive signs and observations. The lull before the storm I think.

SportsTradrer - That is by far one of the most considered, intelligent and helpful posts I have read on here for a long time. That basically sums it up and is all anyone needs to know.

JB - Thankfully I have you filtered; but if you have CF’s mobile number why on earth don’t you just call him and vent all your angry complaints to the man himself, rather than defaming him on here and boring everyone with your negativity and moaning, which is unhelpful and achieves absolutely nothing? I suggest the simple and honest answer is you clearly haven’t got the balls and prefer to anonymously hide behind a keyboard criticising and abusing a man who you know won’t answer back and who is doing a job I suspect is far beyond your capabilities.

Hallsworthy. Yes, all written by Walbrook. Copied and pasted the complete email.

It is a reminder that the fundamentals, leadership and potential, which should always be the reasons one invests in a company, remain strong and the current sp simply does not reflect this. This is an undervalued company and the market will recognize this in time. I also believe once the spin outs are complete more II's will come on board. Patience and nerve are required - essential investment traits. The impatient and nervous are currently being flushed out - not necessarily a bad thing.

This was missing from the beginning of the previous post:

Expansion of COVID-19 characterisation study 20 further volunteers (14 July)

Continued…..

20 further volunteers (14 July)

Unfortunately, the excellent progress made by the Company in recent months has been hampered by retail selling, we all know the small cap AIM stocks have been having a difficult six months across the board and Open Orphan along with many other similar stocks on AIM have found a significant amount of unexpected retails selling over that period. There is some belief that some of this market selling is to do with a large group retail investors who entered the market in April / May 2020 and many of whom had been furloughed at home and used their time very productively while furloughed to actively research, follow, and invest in small AIM stocks with promise, particularly those with potential upside as a result of the pandemic. As a result of the wind down of furlough, a large amount of this group of new retail have returned to work and as such don’t have time to research small cap stocks and as such, many are cashing in the profits and leaving the market and hence that is our belief what is driving the retail sell off in the past six months.

Currently, management does not believe the share price represents the true value of the Company and its growth potential and going forward it believes that its strategy of growing its core business and monetising non-core assets will result in value for shareholders being realised.

Kind regards,
Louis

I have this morning received the following reply to my email sent to Walbrook yesterday expressing my concerns and those of other committed LTH holders on this board regarding the continued fall in the sp:

Thank you for your feedback which will be passed onto the Company.

Cathal has received feedback from investors and advisers on investor communications and he will adapt his approach. Going forward, Cathal does not want his own considerable optimism regarding the Company, which is outlined by his recent share purchase, to cause undue expectation in the market – but instead wait for these milestones to come to fruition and update shareholders accordingly.

Under Cathal’s leadership, however, the Company has transformed into a cash generative business regularly delivering substantial contracts and significant value for shareholders. 2021 has been a transformative year for the business, with EBITDA profitability confirmed at the interim stage which is expected to continue to the year end. It is worth noting that hVIVO and Venn were both significant loss-making businesses until Open Orphan acquired them. Both are now profit-making businesses with significant growth potential and synergies.

The highlights from the Company’s transformative 2021 are outlined below:

Substantial growth in core services business

· £7.5m RSV contract (26 March)
· Significant HRV & Influenza contract w/ AIM Imm (9 July)
· £8.1m Asthma contract (24 August)
· £5.7m Influenza contract (20 September)
· £5.1m RSV contract (17 November)

Announceable contracts for Venn

· Contract renewal w/ top-3 pharmaceutical client (6 January)
· Contract extension w/ Carna Biosciences (1 February)
· New contract w/ Oxford BioTherapeutics (9 March)
· New contract for Breda office (14 July)
· DNDi Phase II trial support (29 July)
· £1.5m contract renewal for Venn Life Sciences (15 November)

Capacity increase

· New 19-bedroom quarantine facility (3 February)
· Expansion of volunteer recruitment centres (20 January)
· COVID study taking place in 19-bed quarantine facility at Royal Free

Improved offering w/ expanded portfolio of human challenge models and expertise

· Added a Malaria Human Challenge model (9 August)
· Acquisition of CHIMagents completed, now integrated into company (14 July)
· Significant CRO experience added to the board in Yamin 'Mo' Khan (13 October)

Progress on monetisation of non-core assets

· Spin out of Poolbeg Pharma / £25m raise w/ £50m valuation (14 July)
· Launch of Disease in Motion (9 April)
· Imutex positive Phase I study results (19 November)

Seized covid opportunity

· Ethics approval for world's first COVID-19 characterisation study (17 February)
· £3m contract to manufacture COVID-19 challenge virus (10 May)
·

SeenRight - I share your concern and your pain. However, regardless of the sp and despite personally sitting on a six figure paper loss on ORPH, I remain focussed on the fact it is a healthy company under good leadership with huge potential, which will in time bear fruit for shareholders.

As any experienced investor knows, there are only ever two options - either sell and move on OR remain invested and be calm and patient. Something some individuals on this board could do well to remember.

Lol. Will post all replies received.

…….company has a bright future.

I emailed Walbrook (ORPH PR company) this morning and got a prompt response confirming they will “forward my comments to the company”. They have always responded promptly in the past. I stressed the concern and disenchantment that even LTH’s are beginning to feel as a result of the falling sp and recent lack of communication from Cathal; which, along with some recent large sellers, suppressed what should have been a good rise on the back of the three very positive recent RNS’s.

ORPH is a healthy company and both it, POLB and the planned spin outs have great potential. ORPH is greatly undervalued and I continue to have complete faith in Cathal’s leadership. This

Tranches of 100,000 shares sold every bl***y day!

Well said, FTC. The strong fundamentals not only remained unchanged but continue to improve. In time the SP will reflect this. In the meantime, the nervous and timid can carry on fretting and complaining. .

….does it take to move this SP?

Well done Cathal and team, yet again. Let’s hope the large seller(s) don’t cancel out the increase in SP we should be seeing on the back of these significant and impressive RNS’s, as has been the case recently.

….off loading multiple tranches of 50,000 - 100,000 shares on a daily basis? Such a shame the positive affect of (significant) RNS’s on the SP is repeatedly cancelled out by large sellers. So frustrating. However, the fundamental health and potential of ORPH will ultimately win through. Still a strong buy. I hold.

That pretty well sums it up. The current ORPH SP doesn’t reflect the health of the company - but there is no doubt it will in time and the impatient, nervous sellers will be kicking themselves.

Reply received this morning from IR:

Open Orphan has first-class cybersecurity which was strengthened further as part of their partnership with the government.

Kind regards,
Louis

Louis Ashe-Jepson
Associate